Alexander M.M. Eggermont, MD, PhD, on Adjuvant Therapy for High-Risk Melanoma
Posted: Saturday, October 20, 2018
Alexander M.M. Eggermont, MD, PhD, of Gustave Roussy, discusses findings from recent adjuvant trials in high-risk melanomamelanoma and the current treatment landscape recommend in light of such data as results on dabrafenib plus trametinib vs anti–PD-1 treatments (nivolumab or pembrolizumab) and the new standard for wild-type disease.